Regulus Therapeutics Inc.
NASDAQ:RGLS
1.49 (USD) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 10.006 | 6.832 | 0.072 | 0.072 | 1.194 | 20.759 | 7.669 | 19.569 | 12.7 | 13.789 | 8.601 |
| Cost of Revenue
| 21.152 | 0.122 | 0.459 | 0.015 | 0.012 | 33.975 | 54.591 | 64.305 | 56.387 | 41.046 | 29.942 | 0.02 | 0 | 0 |
| Gross Profit
| -21.152 | -0.122 | -0.459 | 9.991 | 6.82 | -33.903 | -54.519 | -63.111 | -35.628 | -33.377 | -10.373 | 12.68 | 13.789 | 8.601 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0.998 | 0.998 | -470.875 | -757.208 | -52.857 | -1.716 | -4.352 | -0.53 | 0.998 | 1 | 1 |
| Reseach & Development Expenses
| 21.152 | 18.41 | 17.794 | 15.347 | 12.349 | 33.975 | 53.192 | 64.305 | 56.387 | 41.046 | 29.942 | 20.342 | 17.289 | 20.178 |
| General & Administrative Expenses
| 9.957 | 9.829 | 10.022 | 8.814 | 11.317 | 12.86 | 17.011 | 18.391 | 19.13 | 11.533 | 7.429 | 4.932 | 0 | 0 |
| Selling & Marketing Expenses
| -0.082 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 9.957 | 9.829 | 10.022 | 8.814 | 11.317 | 12.86 | 17.011 | 18.391 | 19.13 | 11.533 | 7.429 | 4.932 | 3.637 | 3.921 |
| Other Expenses
| -21.152 | -0.083 | 0.009 | -1.575 | -1.757 | -1.884 | 0 | 0 | 0 | 0 | 0 | 0 | 3.637 | 3.921 |
| Operating Expenses
| 9.957 | 28.239 | 27.816 | 24.161 | 23.666 | 46.835 | 70.203 | 82.696 | 75.517 | 52.579 | 37.371 | 25.274 | 20.926 | 24.099 |
| Operating Income
| -31.109 | -28.239 | -27.816 | -14.155 | -16.834 | -46.763 | -70.131 | -81.502 | -54.758 | -44.91 | -17.802 | -12.574 | -7.137 | -15.498 |
| Operating Income Ratio
| 0 | 0 | 0 | -1.415 | -2.464 | -649.486 | -974.042 | -68.26 | -2.638 | -5.856 | -0.91 | -0.99 | -0.518 | -1.802 |
| Total Other Income Expenses Net
| 1.073 | -0.083 | 0.009 | -1.575 | -1.757 | -1.884 | -1.971 | -0.338 | -1.008 | -11.769 | -0.889 | -4.707 | 0.001 | -0.091 |
| Income Before Tax
| -30.036 | -28.322 | -27.807 | -15.73 | -18.591 | -48.647 | -72.102 | -81.84 | -55.766 | -56.679 | -18.691 | -17.418 | -7.396 | -15.589 |
| Income Before Tax Ratio
| 0 | 0 | 0 | -1.572 | -2.721 | -675.653 | -1,001.417 | -68.543 | -2.686 | -7.391 | -0.955 | -1.371 | -0.536 | -1.812 |
| Income Tax Expense
| 0.001 | 0.001 | 0.001 | -0.467 | 0.001 | 0.062 | -0.197 | -0.004 | -0.018 | 0.001 | -0.023 | -0.01 | 0.206 | -0.03 |
| Net Income
| -30.037 | -28.323 | -27.808 | -15.263 | -18.592 | -48.709 | -71.905 | -81.836 | -55.748 | -56.68 | -18.668 | -17.408 | -7.602 | -15.559 |
| Net Income Ratio
| 0 | 0 | 0 | -1.525 | -2.721 | -676.514 | -998.681 | -68.539 | -2.685 | -7.391 | -0.954 | -1.371 | -0.551 | -1.809 |
| EPS
| -1.58 | -1.86 | -3.24 | -4.36 | -10.77 | -55.87 | -114.7 | -185.94 | -130.12 | -154.27 | -58.22 | -254.37 | -3,554 | -7,273.96 |
| EPS Diluted
| -1.58 | -1.86 | -3.24 | -4.36 | -10.77 | -55.87 | -114.7 | -185.94 | -130.12 | -154.27 | -58.22 | -254.37 | -3,554 | -7,273.96 |
| EBITDA
| -30.882 | -28.239 | -27.816 | -14.155 | -16.834 | -46.763 | -68.16 | -81.164 | -53.75 | -33.141 | -16.913 | -11.447 | -6.098 | -14.733 |
| EBITDA Ratio
| 0 | 0 | 0 | -1.415 | -2.464 | -649.486 | -946.667 | -67.977 | -2.589 | -4.321 | -0.864 | -0.901 | -0.442 | -1.713 |